MRI contrast agent in the spinal canal to investigate transportation of the cerebrospinal fluid in the brain.
Key facts
- Phase
- Phase 1/2
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorTrial details
- Who runs it
- Region Vaesterbotten
- Trial code
- EU 2024-520146-33-00
- Record updated
- 23 July 2026
- Original description
To quantify the distribution and rate of elimination of the contrast agent as assessed by repeated MRI in humans. We will also document any adverse events related to the administration of GadovistRead full original descriptionShow less
Intrathecal contrast-enhanced MRI for investigation of cerebrospinal fluid transportation
To quantify the distribution and rate of elimination of the contrast agent as assessed by repeated MRI in humans. We will also document any adverse events related to the administration of Gadovist
Inclusion: Patients investigated for suspected idiopathic normal pressure hydrocephalus at Umeå University hospital; Patients with Alzheimers disease; Healthy controls.
Exclusion: Current treatment with anticoagulation medication; Previous investigation with gadolinium contrast medium; Liver failure; known contradicting allergies; Renal impairment (as deffined by blood test at admission); Low threshold for seizures; History of bronchial asthma; Age <65 for INPH. Age <55 years for AD and HC; Mini mental state examination (MMSE) < 20; Not able to understand instructions needed for informed concent; Known contraindications for magnetic reconance imaging.